CAMBRIDGE, Mass., Nov. 1, 2023
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)
("NeuroSense"), a company developing treatments for severe
neurodegenerative diseases, today announced its Chief Medical
Officer Dr. Ferenc Tracik will
participate in the 29th annual BIO-Europe Fall
partnering conference on November 6-8,
2023 in Munich,
Germany.
Dr. Tracik is scheduled to meet with potential strategic
partners and collaborators regarding NeuroSense's advancing
development pipeline. The Company's lead combination drug PrimeC is
in a global Phase 2b study for
amyotrophic lateral sclerosis (ALS). Other programs include the
treatment of Alzheimer's disease, headed into Phase 2, and
Parkinson's disease now in the pre-clinical phase.
BIO-Europe participants interested in meeting with NeuroSense
may connect through the partnering system or contact NeuroSense
directly at ir@neurosense-tx.com.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a combination
therapy that was granted Orphan Drug Designation by the U.S. Food
and Drug Administration (FDA) and the European Medicines Agency
(EMA). NeuroSense completed a Phase 2a clinical study which
successfully met its safety and efficacy endpoints including
reducing functional and respiratory deterioration and statistically
significant changes in ALS-related biological markers indicating
PrimeC's biological activity. PrimeC is now being evaluated in
PARADIGM, a multinational, 18-month, randomized, placebo-controlled
Phase 2b clinical trial, in people
living with ALS. The study enrolled 69 participants in Israel, Italy, and Canada.
About ALS
Amyotrophic lateral sclerosis (ALS) is an incurable
neurodegenerative disease that causes complete paralysis and death
within 2-5 years from diagnosis. Every year, more than 5,000
patients are diagnosed with ALS in the U.S. alone, with an annual
disease burden of $1 billion. The number of patients with ALS
is expected to grow 24% by 2040 in the U.S. and EU.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
For additional information, we invite you to visit
our website and follow us
on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding the cash runway of the Company,
the timing of clinical top-line results of, the results of, the
PARADIGM clinical trial and the timing of a Phase 2 study for
Alzheirmer's disease and patient enrollment regarding a Phase 3
pivotal ALS study of PrimeC. Further, certain forward-looking
statements are based on assumptions as to future events that may
not prove to be accurate. The future events and trends may not
occur and actual results could differ materially and adversely from
those anticipated or implied in the forward looking statements.
These risks include unexpected R&D costs or operating expenses,
a delay in the reporting of clinical top-line results from PARADIGM
clinical trial, a delay in patient enrollment for a Phase 2 study
for Alzheirmer's disease or its planned Phase 3 pivotal ALS study
of PrimeC; the potential for PrimeC to safely and effectively
target ALS; preclinical and clinical data for PrimeC; the timing of
current and future clinical trials, timing for reporting data; the
development and commercial potential of any product candidates of
the company; and other risks and uncertainties set forth in
NeuroSense's filings with the Securities and Exchange Commission
(SEC)., You should not rely on these statements as representing our
views in the future. More information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Annual Report on Form 20-F filed with the
Securities and Exchange Commission on March
22, 2023. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense Therapeutics
Ltd. undertakes no duty to update such information except as
required under applicable law.
Logo:
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-to-participate-in-bio-europe-fall-301973867.html
SOURCE NeuroSense